Skip to content

Immunogenicity and safety of two doses live attenuated varicella vaccine with different intervals schedule in children

Immunogenicity and safety of two doses live attenuated varicella vaccine with different intervals schedule in children

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-PNRC-13003527
Enrollment
Unknown
Registered
2013-08-29
Start date
2013-08-30
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

varicella

Interventions

3 months interval schedule:varicella vaccine
1 year interval schedule:varicella vaccine
3 years interval schedule:varicella vaccine
5 years interval schedule:varicella vaccine

Sponsors

Zhejiang Provincial Center for Disease Control and Prevention
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. Health children age 1-7 years old; 2. No history of clinical chickenpox; 3. Health children age 1-7 years old; 4. No history of clinical chickenpox; 5. Body temperature =37.5? in the vaccinate day; 6. With the corresponding immunization history of varicella vaccine; 7. 12 months, without contraindication of live attenuated varicella vaccine; Informed consent were signed by the parents or guardians; individuals could comply with the requirements of the clinical trials according to the judgment of investigators.

Exclusion criteria

Exclusion criteria: 1. Had any significant contact with anyone with varicella or herpes zoster during preceding 4 weeks; 2. Were immunocompromised or receiving immunosuppressive therapy; 3. Had a history of sensitivity to neomycin, or had allergic reactions to any previous vaccinations; 4. No vaccines other than oral polio were allowed within 1 month before or after study vaccine administration, and no immune globulin or blood product was a llowed in the 3 months before varicella vaccination; 5. exiting the clinical trials automatically; may affect test assessment according to the judgment of the investigators.

Design outcomes

Primary

MeasureTime frame
positive rate;

Secondary

MeasureTime frame
Antibody Level;

Countries

China

Contacts

Public ContactShuyun Xie
shyxie@cdc.zj.cn+86 0571-87115277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026